Point72 DIFC Ltd Has $32.47 Million Stake in Bruker Co. (NASDAQ:BRKR)

Point72 DIFC Ltd raised its holdings in Bruker Co. (NASDAQ:BRKR) by 4,875.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 470,171 shares of the medical research company’s stock after buying an additional 460,722 shares during the period. Bruker comprises about 1.1% of Point72 DIFC Ltd’s holdings, making the stock its largest position. Point72 DIFC Ltd’s holdings in Bruker were worth $32,470,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. First Horizon Advisors Inc. boosted its position in shares of Bruker by 120.4% during the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock valued at $25,000 after buying an additional 218 shares during the last quarter. True Wealth Design LLC boosted its holdings in Bruker by 4,636.4% during the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock worth $36,000 after acquiring an additional 510 shares during the last quarter. UMB Bank n.a. grew its stake in shares of Bruker by 115.3% in the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock worth $46,000 after acquiring an additional 354 shares in the last quarter. Gordian Capital Singapore Pte Ltd purchased a new stake in shares of Bruker in the second quarter valued at about $52,000. Finally, GAMMA Investing LLC lifted its position in shares of Bruker by 81.0% during the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock valued at $60,000 after purchasing an additional 388 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have issued reports on BRKR. Barclays reduced their price objective on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. TD Cowen reduced their target price on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a report on Wednesday, November 6th. Citigroup dropped their price target on Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Wells Fargo & Company reduced their price objective on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research note on Wednesday, November 6th. Finally, Wolfe Research cut Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. One analyst has rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $79.36.

Bruker Price Performance

BRKR opened at $57.55 on Wednesday. Bruker Co. has a twelve month low of $48.07 and a twelve month high of $94.86. The company has a market capitalization of $8.72 billion, a price-to-earnings ratio of 27.67, a PEG ratio of 3.92 and a beta of 1.18. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24. The firm has a 50-day moving average price of $60.23 and a 200-day moving average price of $63.67.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Bruker had a return on equity of 21.52% and a net margin of 9.41%. The company had revenue of $864.40 million during the quarter, compared to the consensus estimate of $866.46 million. During the same period in the previous year, the business earned $0.74 earnings per share. Bruker’s revenue was up 16.4% on a year-over-year basis. Equities analysts expect that Bruker Co. will post 2.4 EPS for the current year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Monday, December 2nd will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.35%. The ex-dividend date of this dividend is Monday, December 2nd. Bruker’s payout ratio is 9.62%.

Insider Activity

In other Bruker news, CEO Frank H. Laukien acquired 100,000 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were bought at an average price of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the transaction, the chief executive officer now owns 38,439,563 shares of the company’s stock, valued at approximately $1,927,359,688.82. This represents a 0.26 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 28.30% of the stock is owned by company insiders.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.